Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia

Qi Zhang; He Li; Xuelan Chen; Fan Gu; Lanxin Zhang; Lu Zhang; Tong Chen; Qiang Chen; Wentong Meng; Yu Wu; Hong Chang; Ting Liu; Chong Chen; Hongbing Ma; Yu Liu

doi:10.1182/blood.2023020619

Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia

Blood. 2023 Oct 26;142(17):1494-1499. doi: 10.1182/blood.2023020619.

Authors

Qi Zhang¹, He Li², Xuelan Chen¹, Fan Gu¹, Lanxin Zhang¹, Lu Zhang¹, Tong Chen³, Qiang Chen⁴, Wentong Meng⁵, Yu Wu², Hong Chang², Ting Liu², Chong Chen¹, Hongbing Ma², Yu Liu¹

Affiliations

¹ Department of Hematology and Institute of Hematology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
² Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
³ Sichuan Hua Xi Kindstar Medical Diagnostic Centre, Chengdu, Sichuan, China.
⁴ Sichuan Neo-Life Stem Cell Biotech Inc, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan, China.
⁵ Laboratory of Stem Cell Biology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

PMID: 37624915
DOI: 10.1182/blood.2023020619

Abstract

Here we report a new fusion gene, STRN3-RARA, in acute promyelocytic leukemia (APL). It cooperates with UTX deficiency to drive full-blown APL in mice. Although STRN3-RARA leukemia quickly relapses after all-trans retinoic acid treatment, it can be restrained by cepharanthine.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Leukemia, Promyelocytic, Acute* / drug therapy
Leukemia, Promyelocytic, Acute* / genetics
Mice
Oncogene Proteins, Fusion / genetics
Tretinoin / therapeutic use

Substances

Oncogene Proteins, Fusion
Tretinoin
Rara protein, mouse
Strn3 protein, mouse